Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a diabetes drug shield kidneys in lupus?

NCT ID NCT07700940

Disease control Sponsor: Ahmed Yehia Ismail Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 14, 2026 · Last updated Jul 16, 2026 · Updated 2 times

Summary

This trial investigates whether empagliflozin, a drug already used to protect kidneys in diabetes, can also benefit people with lupus nephritis—a serious kidney complication of lupus. Researchers will compare empagliflozin plus standard care against a placebo plus standard care in 66 adults with active lupus nephritis. The main goal is to see if the drug improves kidney function and reduces protein in the urine over three months.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
empagliflozin 25 mg tablet
What this could lead to
If it works, this could offer a new way to protect kidney function in people with lupus nephritis, potentially slowing disease progression.
What could go wrong
This is a small, early-phase trial with only 66 participants and a short 3-month treatment period. Results may not apply to all lupus nephritis patients, and side effects are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

About 66 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jan 2024

Expected to finish

Dec 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 65 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adults (≥ 18 years) with established biopsy-proven LN of active III, IV, overlapping III/IV, or overlapping III/V classes. * eGFR ≥ 30 ml.min1.1.73m-2, * Urinary protein creatinine ratio (uPCR) \> 1000 mg/g. Exclusion Criteria: * Subjects with serious hypersensitivity (angioedema and/or anaphylaxis) to EMPA. * eGFR \< 30 ml.min-1.1.73m-2. * uPCR \< 1000 mg/g. * Type 1 or 2 diabetes. * Aterial fibrillation. * Hepatic impairment \[defined as alanine transaminase or aspartate transaminase \>3 times the upper limit of normal (ULN) or total bilirubin \>2 times the ULN at the time of enrolment\]. * Any condition outside the renal and cardiovascular study area with a life expectancy of \< 6 months based on care provider's clinical judgment. * Those who enrolled in an experimental study in the previous 6 months.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Lupus nephritis (LN) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

lupus nephritis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Lupus nephritis (LN)

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Beni-Suef university hospital

    RECRUITING

    Banī Suwayf, Egypt

More trials for these conditions

Other studies related to the condition(s) this trial covers.